Immunology / Virology & Vaccines

#Biotechnology #Cancer research #Immunology / Virology & Vaccines #Immunotherapy #mRNA

Consortium awarded EU Commission TIGER Grant of €6.9 million

eTheRNA Immunotherapies, a clinical-stage company developing mRNA-based immunotherapies as off-the-shelf products for the treatment of cancer and infectious diseases, has announced the award of a TIGER grant of €6.9 million from the EU commission. The grant was awarded to a consortium led by eTheRNA and will be used to accelerate the development of… Read More

#Cancer Research #News

#Biopharmaceutical #Covid-19 #Immunology / Virology & Vaccines #Sputnik

RDIF and Stelis Biopharma partner to vaccinate 100 million with Sputnik V

The Russian Direct Investment Fund (RDIF) and Stelis Biopharma, the biopharmaceutical division of Strides, a global pharmaceutical company headquartered in India, have partnered to produce and supply a minimum of 200 million doses of the Russian Sputnik V vaccine against COVID-19, sufficient to vaccinate 100 million people. Sputnik V is now approved for… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Cell and protein analysis #Covid-19 #Immunology / Virology & Vaccines #Podcast

Advances in cell and protein analysis for virology research – podcast

This exclusive podcast features Dr Hongshan Li, Applications Manager, Sartorius, discussing advances in cell and protein analysis for virology research. This episode examines virology research – what’s currently happening in the sector and how new advances in technology are helping push forward innovation and drug development. With COVID-19 playing such… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Drug development #Drug discovery #Immunology / Virology & Vaccines #Podcast #Sartorius

Advances in cell and protein analysis for virology research

This free to listen podcast and DDW exclusive, features Dr Hongshan Li, Applications Manager, Sartorius, discussing advances in cell and protein analysis for virology research. This episode only available to download here, examines virology research – what’s currently happening in the sector and how new advances in technology are helping push forward… Read More

#Podcasts

#Biopharmaceutical #Covid-19 #Immunology / Virology & Vaccines

Medicago and GSK start Phase III trial of COVID-19 vaccine candidate

Medicago, a biopharmaceutical company headquartered in Quebec City, and GlaxoSmithKline (GSK) have begun Phase III clinical testing of Medicago’s plant-derived COVID-19 vaccine candidate in combination with GSK’s pandemic adjuvant, as part of the ongoing Phase II/III study. Medicago received approval from Canadian and U.S. regulatory authorities to proceed with enrolment… Read More

#Covid-19 #News

#Covid-19 #Drug delivery #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna starts vaccine trials on babies and children

Moderna has announced that the first participants have been dosed in the Phase II/II study, called the KidCOVE study, of mRNA-1273, the company’s vaccine candidate against COVID-19, in children ages 6 months to less than 12 years. The study is being conducted in collaboration with the National Institute of Allergy and… Read More

#Covid-19 #Editor's Choice #News

#Covid-19 #Immunology / Virology & Vaccines #Moderna #mRNA

Moderna doses first patients for its next generation COVID-19 vaccine

Moderna has announced that the first participants have been dosed in the Phase I study of mRNA-1283, the company’s next generation COVID-19 vaccine candidate. mRNA-1283 is being developed as a potential refrigerator stable mRNA vaccine that will facilitate easier distribution and administration by healthcare providers Stéphane Bancel, Chief Executive Officer… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Clinical trial #Covid-19 #Immunology / Virology & Vaccines #mRNA

Sanofi and Translate Bio begin clinical trial of COVID-19 vaccine

Sanofi Pasteurand Translate Bio, a clinical-stage mRNA therapeutics company, have announced the start of the Phase I/II clinical trial for MRT5500, an mRNA vaccine candidate against SARS-CoV-2. The companies expect interim results from this trial in the third quarter of 2021. Thomas Triomphe, Executive Vice President and Global Head of… Read More

#Covid-19 #News

#AstraZeneca #Covid-19 #Drug development #Immunology / Virology & Vaccines #Moderna #Pfizer

COVID-19 booster shots more likely than vaccines due to variants

Data analytics company, GlobalData says that if new SARS-CoV-2 variants continue to develop, reducing the effectiveness of COVID-19 vaccines and the natural immunity of survivors, then annual booster shots may be required for COVID-19 immunity. Johanna Swanson, Product Manager at GlobalData, said: “Of the several natural variants that have recently been… Read More

#Covid-19 #News

#Biopharmaceutical #Covid-19 #Drug delivery #Immunology / Virology & Vaccines

Novartis and CureVac sign COVID-19 vaccine candidate agreement

Novaratis has signed an initial agreement to manufacture biopharmaceutical company CureVac’s COVID-19 vaccine candidate, CVnCoV. Following final agreement, Novartis plans to start manufacturing of the mRNA and bulk drug product in the second quarter of 2021. It is anticipated to produce up to 50 million doses by the end of… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines

Professor Sarah Gilbert wins award for her work on the Oxford vaccine

The lead researcher on the Oxford vaccine team, Professor Gilbert is Professor of Vaccinology in the Nuffield Department of Medicine at the University of Oxford. She is the Oxford Project Leader for ChAdOx1 nCoV-19, a vaccine against the novel coronavirus, SARSCoV-2, with approval for use in many countries around the… Read More

#Covid-19 #Editor's Choice #News #Trending News

#AstraZeneca #Covid-19 #Immunology / Virology & Vaccines #Pfizer #Study

Study shows effectiveness of one dose of COVID-19 vaccine in over 80s

Interim study results show the effectiveness of one dose of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines in preventing hospitalisation of people in their 80s with multiple comorbidities. The AvonCAP study results are by researchers from the University of Bristol, University Hospitals Bristol and Weston NHS Foundation Trust (UHBW) and North Bristol… Read More

#Covid-19 #News

#Covid-19 #Immunology / Virology & Vaccines #mRNA

UK government invests £5m into Covid-19 variant vaccines

Budget Chancellor Rishi Sunak announced a £5 million investment in CPI to develop an mRNA ‘vaccine library’, as part of the government’s vaccines support package. The vaccine library will form the basis of a rapid response facility, enabling mRNA vaccines to be developed to help protect against new variants of… Read More

#News #Trending News

#Immunology / Virology & Vaccines #Life sciences #mRNA #Pharmaceutical

What the UK Budget means for the pharma sector: industry reaction

By Lu Rahman In his 2021 Budget, UK Chancellor of the Exchequer, Rishi Sunak, announced a range of measures designed to benefit UK science, business and technology. These included tax breaks for firms to designed to ‘unlock’ £20bn worth of business investment; incentives for companies to take on apprentices; allowing… Read More

#Editor's Choice #News #Trending News

#Covid-19 #Immunology / Virology & Vaccines #Life sciences

Despite COVID-19, Swedish life science companies in growth mode

A new survey conducted by SwedenBIO shows that Swedish life science companies are more confident about future growth than they were before COVID-19, with 80% planning for new hires and expansion. The survey shows a major upswing in the industry, following on from similar reports a year ago which demonstrated… Read More

#Covid-19 #News